Cargando…

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes

Cancer is a genetic disease, but two patients rarely have identical genotypes. Similarly, patients differ in their clinicopathological parameters, but how genotypic and phenotypic heterogeneity are interconnected is not well understood. Here we build statistical models to disentangle the effect of 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerstung, Moritz, Pellagatti, Andrea, Malcovati, Luca, Giagounidis, Aristoteles, Porta, Matteo G Della, Jädersten, Martin, Dolatshad, Hamid, Verma, Amit, Cross, Nicholas C. P., Vyas, Paresh, Killick, Sally, Hellström-Lindberg, Eva, Cazzola, Mario, Papaemmanuil, Elli, Campbell, Peter J., Boultwood, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Pub. Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338540/ https://www.ncbi.nlm.nih.gov/pubmed/25574665 http://dx.doi.org/10.1038/ncomms6901

Ejemplares similares

Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes
por: Pellagatti, Andrea, et al.
Publicado: (2008)

The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts
por: Boultwood, Jacqueline, et al.
Publicado: (2008)

The U2AF1(S34F) mutation induces lineage-specific splicing alterations in myelodysplastic syndromes
por: Yip, Bon Ham, et al.
Publicado: (2017)

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
por: Bello, Erica, et al.
Publicado: (2015)

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells
por: Dolatshad, H, et al.
Publicado: (2015)

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells
por: Dolatshad, H, et al.
Publicado: (2015)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
por: Malcovati, Luca, et al.
Publicado: (2011)

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes
por: Dolatshad, H, et al.
Publicado: (2016)

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
por: Scharenberg, Christian, et al.
Publicado: (2017)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome
por: Botezatu, Lacramioara, et al.
Publicado: (2016)

Subclonal variant calling with multiple samples and prior knowledge
por: Gerstung, Moritz, et al.
Publicado: (2014)

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression
por: Pellagatti, A, et al.
Publicado: (2016)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
por: Haase, Detlef, et al.
Publicado: (2019)

Myelodysplastic syndromes
por: Hellström Lindberg, Eva
Publicado: (2018)

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes
por: Giagounidis, Aristoteles A N, et al.
Publicado: (2007)

Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality
por: Dimitriou, Marios, et al.
Publicado: (2016)

ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts
por: Valletta, Simona, et al.
Publicado: (2015)

“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
por: Rasmussen, Bengt, et al.
Publicado: (2022)

Recent Advances in the 5q- Syndrome
por: Pellagatti, Andrea, et al.
Publicado: (2015)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome
por: Guzzi, Nicola, et al.
Publicado: (2022)

Myelodysplastic syndromes: moving towards personalized management
por: Hellström-Lindberg, Eva, et al.
Publicado: (2020)

SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications
por: Singh, Shalini, et al.
Publicado: (2020)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs
por: Asimomitis, Georgios, et al.
Publicado: (2022)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
por: Blum, Sabine, et al.
Publicado: (2021)

A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome
por: Ueda, Yasutaka, et al.
Publicado: (2014)

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
por: Alessandrino, Emilio Paolo, et al.
Publicado: (2013)

Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics
por: Fernandez-Mercado, Marta, et al.
Publicado: (2012)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes
por: Della Porta, Matteo G., et al.
Publicado: (2017)

Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression
por: Kazachenka, Anastasiya, et al.
Publicado: (2019)

Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
por: Woll, Petter S., et al.
Publicado: (2022)

Importance of Classical Morphology in the Diagnosis of Myelodysplastic Syndrome
por: Invernizzi, Rosangela, et al.
Publicado: (2015)

Molecular genetics in clinical decision making for patients with myelodysplastic syndromes or related disorders
por: Cazzola, Mario
Publicado: (2018)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts
por: Conte, Simona, et al.
Publicado: (2015)

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3b2f2uom99ovk1fcs3i4sff25h